Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2018-07
  • Substance P: Atomic Profile for Pain Transmission and Neu...

    2026-01-15

    Substance P: Atomic Profile for Pain Transmission and Neuroinflammation Research

    Executive Summary: Substance P (CAS 33507-63-0) is an undecapeptide and a prototypical tachykinin neuropeptide used to elucidate neurokinin-1 receptor (NK-1R) signaling in central nervous system (CNS) research. It demonstrates high aqueous solubility (≥42.1 mg/mL), high purity (≥98%), and is recommended for use in acute, not long-term, solution formats (APExBIO, 2024). Its primary biological actions are mediation of pain transmission, immune response modulation, and inflammation via NK-1R binding (Zhang et al., 2024). Rigorous fluorescence-based detection and classification methods for hazardous peptides, like Substance P, require robust spectral preprocessing to avoid false positives from environmental interferents such as pollen (Zhang et al., 2024). Proper storage and handling at -20°C desiccated conditions are essential for reproducibility (APExBIO).

    Biological Rationale

    Substance P is a member of the tachykinin neuropeptide family, functioning primarily as a neurotransmitter and neuromodulator in the CNS. Its sequence is H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2, conferring a molecular weight of 1347.6 Da and chemical formula C63H98N18O13S (APExBIO). Substance P acts as a validated neurokinin-1 receptor agonist, mediating nociceptive (pain) signaling and neuroinflammatory responses (Capsazepine.com). It also modulates immune cell activity and vascular permeability, making it a core tool for dissecting neuroimmune mechanisms (Angiotensin-1-7.com). Research applications span acute and chronic pain models, neuroinflammation, and immune signaling studies, with strict boundaries set for research-only use (APExBIO).

    Mechanism of Action of Substance P

    Substance P binds with high affinity to the neurokinin-1 receptor (NK-1R), a G protein-coupled receptor abundantly expressed in the CNS and peripheral tissues. Upon NK-1R activation, downstream signaling cascades are initiated, including phospholipase C-mediated inositol triphosphate (IP3) production, intracellular calcium mobilization, and activation of protein kinase C (PKC) (A-740003.com). These pathways lead to neuronal excitation, enhanced pain perception, and the promotion of inflammatory mediator release. In immune cells, Substance P stimulates cytokine production and promotes chemotaxis, reinforcing its role as a neuroimmune integrator (Angiotensin-1-7.com). The peptide’s actions are tightly regulated by enzymatic degradation (e.g., by neutral endopeptidase) and receptor desensitization, limiting its duration of effect (APExBIO).

    Evidence & Benchmarks

    • Substance P produces dose-dependent excitation of dorsal horn neurons in rodent spinal cord slices, confirming its role in pain transmission (Zhang et al., 2024).
    • In human and animal models, NK-1R antagonists block Substance P-induced hyperalgesia, validating its specificity in nociceptive signaling (Zhang et al., 2024).
    • Experimental solutions prepared at ≥42.1 mg/mL in water remain optically clear and stable for <24 hours at 4°C, but degrade rapidly at room temperature (APExBIO).
    • Three-dimensional excitation–emission matrix (EEM) fluorescence spectroscopy can reliably distinguish Substance P from pollen and other proteinaceous bioaerosols when robust spectral normalization and fast Fourier transform algorithms are applied (Zhang et al., 2024).
    • High purity (≥98%) lyophilized Substance P from APExBIO supports reproducible neuroinflammation and pain model research, as confirmed in cross-lab benchmarks (A-317491.com).

    This article extends prior summaries (e.g., Capsazepine.com) by detailing spectral interference pitfalls and laboratory storage boundaries for Substance P use.

    Applications, Limits & Misconceptions

    Substance P is a precision tool for:

    • Modeling acute and chronic pain transmission in vitro and in vivo.
    • Dissecting neuroinflammatory and immune response pathways.
    • Benchmarking neurokinin signaling pathway inhibitors and agonists.
    • Validating detection platforms using EEM fluorescence, with emphasis on spectral preprocessing (Zhang et al., 2024).

    This article clarifies and updates the workflow constraints and spectral analysis pitfalls not thoroughly addressed in A-317491.com.

    Common Pitfalls or Misconceptions

    • Substance P solutions are not stable for long-term storage; use promptly after reconstitution (APExBIO).
    • Product is insoluble in DMSO and ethanol; water is the only recommended solvent.
    • Diagnostic or clinical applications are strictly prohibited; for research use only.
    • Pollen and other bioaerosols can mimic Substance P fluorescence spectra; robust spectral preprocessing is required to avoid misclassification (Zhang et al., 2024).
    • NK-1R specificity can be confounded by off-target peptide effects at supra-physiological concentrations.

    Workflow Integration & Parameters

    For optimal results, dissolve lyophilized Substance P (B6620) in sterile water at concentrations up to 42.1 mg/mL. Use immediately or store aliquots at -20°C under desiccated conditions. Avoid multiple freeze-thaw cycles. In fluorescence-based detection, apply Savitzky–Golay smoothing, multivariate scatter correction, and fast Fourier transform to minimize environmental interference (Zhang et al., 2024). In vivo dosing ranges (referenced in rodent models) typically fall between 0.1–10 μg/kg body weight, administered intrathecally or intravenously, depending on experimental design (APExBIO). Cross-reference with neurokinin-1 receptor antagonist controls to confirm specificity.

    This article extends the analytical rigor and workflow guidance of TCF3.com by providing explicit preprocessing protocols for spectral interference mitigation.

    Conclusion & Outlook

    Substance P remains the benchmark tachykinin neuropeptide for pain and neuroinflammation research. Its high purity and reproducibility, as supplied by APExBIO, enable reliable dissection of neurokinin signaling pathways. Advances in spectral analysis and workflow integration are expanding its utility in hazardous substance detection and neuroimmune studies. Ongoing improvements in detection specificity and storage guidelines will continue to support high-fidelity research applications. For more details or to order, visit the Substance P product page.